The 0.61x price-to-sales and 1.00x price-to-book multiples place AVNW far below Ciena (18.7x book) and Calix (3.1x book), consistent with its structurally weaker gross margin of roughly 31% versus the 42%-57% range those peers sustain. However, the book-value anchor is itself questionable given retained earnings of -$574.6M and equity accretion sourced substantially from stock-based compensation rather than profit retention, so the apparent book-value cheapness may overstate real asset backing. The 6.09x PEG is high for a business whose revenue has swung between $88M and $121M, implying the market is pricing an earnings recovery that the historical margin record does not yet support.

Net margin of -1.1% in 2026Q4 versus a 4.8% operating margin confirms the recurring pattern identified in the income statement analysis: operating profit repeatedly fails to reach the bottom line, so operating margin, not net margin, is the cleaner proxy for current earning power. The 2025Q1 trough, with 22.4% gross margin and a -17.6% operating margin, shows how violently profitability can swing on revenue lumpiness, which means single-quarter margin readings should not be annualized. On a normalized basis, mid-single-digit operating margins appear to be AVNW's realistic earning power absent a mix shift toward richer product lines.

ROE tells the same story with more noise, ranging from -4.7% to 2.1% and finishing at -0.5%; critically, this ROE is computed on an equity base propped up by stock-based compensation and other non-earnings accretion against -$574.6M of accumulated deficits, so it flatters true returns even at its peaks. Because the asset base is unusually light for a manufacturer (fixed assets near 3.5% of total assets), the low ROIC is driven by margin insufficiency rather than capital intensity. The compounding-versus-decay verdict here is decay: the 2025Q1 capital destruction episode, followed by only modest 1%-2% recoveries, leaves cumulative value creation unproven.

The 0.20x asset turnover in 2026Q4 reflects both the light asset base and sub-scale revenue, but the more consequential signal is DSO compression from 268 to 222 days over the last three quarters, which mechanically explains part of the current-ratio improvement without any improvement in cash on hand. Against DPO near 136-184 days, the supplier-financing float offsets some receivables drag, yet the cash flow analysis shows working capital still consumed $56.2M cumulatively over ten quarters. Investors should monitor whether the DSO improvement persists, as a reversal would likely pull reported operating cash flow back toward the underlying earnings profile.

On absolute measures the balance sheet remains comfortable: a 1.97x current ratio, 1.66x quick ratio, and D/EBITDA of 12.89x (itself inflated by low trailing EBITDA, with prior quarters printing 113.6x) suggest refinancing risk is not imminent. The concern is directional: acquisition-related borrowing has structurally raised the debt base while EBITDA generation remains volatile, so a repeat of the 2025Q1-type operating loss would push coverage back below 1x. Coverage is therefore adequate today but not cushioned, and the deterioration from 8.65x in 2024Q4 to 3.22x in 2026Q4 shows debt service is becoming less comfortable over time.